Assessment of tumor response to immune checkpoint inhibitors using chest magnetic resonance imaging

Assessment of tumor response to immune checkpoint inhibitors using chest magnetic resonance imaging - Assessment of tumor response to immune checkpoint inhibitors using chest magnetic resonance imaging

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000023462

Enrollment

Registered

2016-08-03

Start date

2016-07-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients receiving immune checkpoint therapy. Pathologically diagnosed metastatic/relapse non-small-lung cancer. Evaluable lesion >2cm. ECOG PS 0-2. Estimated prognosis > 3 months. Age >18 years. Informed consent given.

Exclusion criteria

Exclusion criteria: Autoimmune disease. Interstitial lung disease. Severe comorbidities. Uncontrolled central nerve system lesion. Severe renal disorder. Inapplicable for MRI.

Design outcomes

Primary

Measure	Time frame
Evaluation of tumor response 4 weeks after immune checkpoint therapy.	—

Secondary

Measure	Time frame
Evaluation of tumor response 2 and 8 weeks after immune checkpoint therapy.	—

Countries

Japan

Contacts

Public ContactMasato Karayama

Hamamatsu Univ. School of Medicine Department of clinical oncology

karayama@hama-med.ac.jp0534352419

Outcome results